Eli Lilly Stock: Why the Weight-Loss Boom Is Just Beginning

Going Public With Ross Mandell

Ross Mandell delivers a bullish investment thesis on Eli Lilly (LLY), arguing that the company's current dominance in GLP-1 weight-loss and diabetes drugs like Mounjaro and Zepbound is merely the opening act of a much larger

Key takeaways

• Eli Lilly reported ~$23B revenue in Q2 2026, up 48% YoY, driven by Mounjaro (~$10B) and Zepbound (~$5B).
• Oral GLP-1 drug orforglipron (Foundayo) is already approved in the U.S. and UK, capturing over 30% of new oral weight-loss patients despite a recent commercial launch.

Main topics

• GLP-1 weight-loss drugs
• Eli Lilly stock analysis

Notable quotes

"Mounjaro alone generated almost $10 billion in the quarter. Zepbound brought in almost $5 billion."

Conclusion

The episode provides a forward-looking investment framework for Eli Lilly,

Transcript preview

Speaker 1 (0:00) For many of us, going further isn't a choice. It's a feeling we can't ignore because ambition has a way of outgrowing where it began. Speaker 1 (0:11) Turning dreams into direction. Speaker 1 (0:17) Every journey brings us closer to the life we imagine. Speaker 1 (0:23) So, where will your journey take you? Etihad. Beyond Borders. Speaker 3 (0:29) Don't miss a minute of United Soccer League action. The USL Championship and USL League One are on CBS Sports and ESPN platforms all season long. With additional coverage on Sirius XMFC, Channel 188, and select matches available in Spanish on 2DNA, it's your time to take part in building what's next. Visit uslchampionship.com or uslleagueone.com for complete listings. Find your local club and be part. of what's next. Speaker 2 (0:59) Imagine building one of the most valuable pharmaceutical companies in the world and then realizing the drug that changed everything only be the beginning. That's the story I want to talk about today. Everybody knows about Monjaro. Everybody knows about Zepan. Everybody knows people were taking GLP-1 drugs. But while Wall Street is staring at what Eli Lilly has already built, I'm looking at what could come next. A pill. a next-generation triple-action drug. Global expansion. Billions of dollars in new manufacturing. An obesity market that could eventually be worth more than $100 billion a year. And a company that, in my opinion, is trying to own every lane of it. The injection. The pill. The next-generation treatment. The manufacturing. The distribution. The pipeline. The ticket symbol is LLY. Speaker 2 (1:55) What's shaking, everybody? My name is Ross Mandel, and welcome to Going Public. Today, we're talking about Eli Lilly. And this is one of those companies where I want you to just forget the stock price for a minute and understand the machine that's being built underneath it. Because Lilly is not some biotech that appeared yesterday with one hot drug. This company was founded in Indianapolis in 1876. 150 years ago. In 1923, Lilly became the first company to commercially produce insulin. Think about that. More than a century ago, this company was standing at the center of one of the biggest revolutions in diabetes treatment. And now 100 years later, diabetes and obesity have put Lilly right back in the center of another medical revolution. That symmetry is just incredible to me. But here's the difference this time. This isn't only about treating a disease. It's about potentially changing how hundreds of millions of people around the world manage weight, diabetes, cardiovascular risk, and metabolic health. And Wall Street has figured out just how big that could become. The first explosion came from terzipatide. You know the names. Malnjaro for type 2 diabetes. Zepound for obesity. And those two drugs have changed the trajectory of this company. Second quarter of 26, Lilly reported approximately $23 billion in revenue. Up 48 % from the year before. 48 % for a company this size? That is enormous. Malnjaro alone generated almost $10 billion. in the quarter. Zepbound brought in almost $5 billion. Between those two medicines, you're looking at the engines driving one of the fastest growing lots. For many of us, Speaker 1 (4:00) going further isn't a choice. It's a feeling we can't ignore because ambition has a way of outgrowing where it began. Speaker 1 (4:10) Turning dreams into direction. Speaker 1 (4:15) Every journey brings us closer to the life we imagine. Speaker 1 (4:21) So, where will your journey take you? Etihad, beyond borders. Speaker 3 (4:28) Don't miss the USL Championship Final on CBS, November 21st at noon Eastern. Will the Pittsburgh Riverhounds retain their crown? Or will a new title winner emerge? Don't miss the conclusion to the 2026 season, Saturday, November 21st at noon Eastern on CBS. Speaker 2 (4:45) Pharmaceutical companies in the history of the world. And that's where most people stop. They say... Lilly is the Monjaro company. Lilly, it's a Zepbound company. Wrong. That's chapter one. What I think makes this story so interesting is that Lilly appears determined not to protect one blockbuster. They're